Moderate fundamentals with elevated risk parameters
Molbio Diagnostics IPO is currently open with a price band of 768-807. The company has shown revenue growth in recent years, but key valuation metrics are missing.
The company has shown revenue growth in recent years, with revenue increasing from 836.56 cr in 2024 to 1445.68 cr in 2026. However, key valuation metrics are missing.
Key valuation metrics such as PE ratio and EV/EBITDA are missing, and anchor investor data is not available, which affects the overall data quality.
+14.9%
Overall demand
Retail Queue
Institutional Queue
Non-Institutional
Subscribed
Vibrant growth sector
High growth industry driven by energy transition and carbon mitigation.
Promoters group details
Promoter Group holds 72.21% of pre-issue capital.
| Financial Year | Revenue (₹ Cr) | EBITDA Margin (%) | PAT (₹ Cr) | ROCE (%) | ROE (%) | Debt / Equity (x) |
|---|---|---|---|---|---|---|
| 2024 | ₹836.56 Cr | 22.13% | ₹83.54 Cr | 0.00% | 0.00% | 0.00x |
| 2025 | ₹1020.42 Cr | 25.15% | ₹138.58 Cr | 0.00% | 0.00% | 0.00x |
| 2026 | ₹1445.68 Cr | 22.70% | ₹164.14 Cr | 0.00% | 0.00% | 0.00x |
| Company | P/E (x) | ROE (%) | Revenue CAGR (3Y) | EBITDA Margin (%) | Market Cap (₹ Cr) |
|---|---|---|---|---|---|
| Molbio Diagnostics (IPO) | -- | -- | 41.7% | 22.7% | -- |
Subscription Trend (Times)
GMP Trend (₹)
Ideal for investors who:
